{"id":"NCT01951326","sponsor":"RedHill Biopharma Limited","briefTitle":"Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease","officialTitle":"A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09","primaryCompletion":"2018-05","completion":"2019-08","firstPosted":"2013-09-26","resultsPosted":"2020-05-01","lastUpdate":"2020-12-08"},"enrollment":331,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"DRUG","name":"RHB-104","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"RHB-104","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.","primaryOutcome":{"measure":"Remission at Week 26","timeFrame":"Week 26","effectByArm":[{"arm":"RHB-104","deltaMin":61,"sd":null},{"arm":"Placebo","deltaMin":37,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0048"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":103,"countries":["United States","Australia","Bulgaria","Canada","Czechia","Israel","New Zealand","Poland","Serbia","Slovakia"]},"refs":{"pmids":["39199994"],"seeAlso":["http://www.redhillbio.com"]},"adverseEventsSummary":{"seriousAny":{"events":31,"n":166},"commonTop":["Crohn's Disease","Chromaturia","Abdominal Pain","Nausea","Headache"]}}